Home > Healthcare & Medical Devices > Pulmonary Arterial Hypertension Market > Table of Contents

Pulmonary Arterial Hypertension Market Size By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase 5 (PDE-5), Vasodilators), By Route of Administration (Oral, Intravenous, Inhalation), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI1939
  • Base Year: 2020
  • Report Format: PDF

Report Content

Chapter 1   Methodology

1.1    Market definition

1.2    Base estimates & working

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Pulmonary arterial hypertension industry 3600 synopsis, 2016 - 2027

2.1.1    Business trends

2.1.2    Drug class trends

2.1.3    Route of administration trends

2.1.4    Regional trends

Chapter 3   Pulmonary Arterial Hypertension Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1    Increase in prevalence of pulmonary arterial hypertension

3.3.1.2    Strong product pipeline

3.3.1.3    Growing government initiatives

3.3.1.4    Rising global geriatric population

3.3.2    Industry pitfalls & challenges

3.3.2.1    Patent expiration

3.3.2.2    Side effects associated with the drugs

3.4    Growth potential analysis

3.4.1    By drug class

3.4.2    By route of administration

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape, 2020

3.7.1    Company matrix analysis, 2020

3.8    PESTEL analysis

Chapter 4   Pulmonary Arterial Hypertension Market, By Drug Class

4.1    Key segment trends

4.2    Prostacyclin and prostacyclin analogs

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Soluble guanylate cyclase (SGC) stimulators

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.4    Endothelin receptor antagonist (ERA)

4.4.1    Market size, by region, 2016 - 2027 (USD Million)

4.5    Phosphodiesterase 5 (PDE-5)

4.5.1    Market size, by region, 2016 - 2027 (USD Million)

4.6    Vasodilators

4.6.1    Market size, by region, 2016 - 2027 (USD Million)

4.7    Others

4.7.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 5   Pulmonary Arterial Hypertension Market, By Drug Class

5.1    Key segment trends

5.2    Oral

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    Intravenous

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Inhalation

5.4.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 6   Pulmonary Arterial Hypertension Market, By Region

6.1    Key regional trends

6.2    North America

6.2.1    Market size, by country, 2016 - 2027 (USD Million)

6.2.2    Market size, by drug class, 2016 - 2027 (USD Million)

6.2.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.2.4    U.S.

6.2.4.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.2.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.2.5    Canada

6.2.5.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.2.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3    Europe

6.3.1    Market size, by country, 2016 - 2027 (USD Million)

6.3.2    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.4    Germany

6.3.4.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.5    UK

6.3.5.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.6    France

6.3.6.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.7    Spain

6.3.7.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.7.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.3.8    Italy

6.3.8.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.3.8.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4    Asia Pacific

6.4.1    Market size, by country, 2016 - 2027 (USD Million)

6.4.2    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.4    Japan

6.4.4.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.5    China

6.4.5.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.6    India

6.4.6.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.7    Australia

6.4.7.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.7.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.4.8    South Korea

6.4.8.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.4.8.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5    Latin America

6.5.1    Market size, by country, 2016 - 2027 (USD Million)

6.5.2    Market size, by drug class, 2016 - 2027 (USD Million)

6.5.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.4    Brazil

6.5.4.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.5.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.5    Mexico

6.5.5.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.5.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.5.6    Argentina

6.5.6.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.5.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6    Middle East and Africa

6.6.1    Market size, by country, 2016 - 2027 (USD Million)

6.6.2    Market size, by drug class, 2016 - 2027 (USD Million)

6.6.3    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.4    South Africa

6.6.4.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.6.4.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.5    Saudi Arabia

6.6.5.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.6.5.2    Market size, by route of administration, 2016 – 2027 (USD Million)

6.6.6    UAE

6.6.6.1    Market size, by drug class, 2016 - 2027 (USD Million)

6.6.6.2    Market size, by route of administration, 2016 – 2027 (USD Million)

Chapter 7   Company Profiles

7.1    Competitive dashboard, 2020

7.2    Bayer AG

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.2.5    SWOT analysis

7.3    Eli Lilly and Company

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.3.5    SWOT analysis

7.4    Gilead Sciences, Inc.

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.4.5    SWOT analysis

7.5    GlaxoSmithKline plc.

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.5.5    SWOT analysis

7.6    Johnson & Johnson

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.6.5    SWOT analysis

7.7    Pfizer, Inc.

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.7.5    SWOT analysis

7.8    United Therapeutics Corporation

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.8.5    SWOT analysis
 

Data Tables

TABLE 1.    Pulmonary arterial hypertension industry 3600 synopsis, 2016-2027

TABLE 2.    Global pulmonary arterial hypertension market, 2016 – 2020 (USD Million)

TABLE 3.    Global pulmonary arterial hypertension market, 2021 – 2027 (USD Million)

TABLE 4.    Global pulmonary arterial hypertension market, by drug class, 2016 - 2020 (USD Million)

TABLE 5.    Global pulmonary arterial hypertension market, by drug class, 2021 – 2027 (USD Million)

TABLE 6.    Global pulmonary arterial hypertension market, by route of administration, 2016 - 2020 (USD Million)

TABLE 7.    Global pulmonary arterial hypertension market, by route of administration, 2021 – 2027 (USD Million)

TABLE 8.    Global pulmonary arterial hypertension market, by region, 2016 – 2020 (USD Million)

TABLE 9.    Global pulmonary arterial hypertension market, by region, 2021 – 2027 (USD Million)

TABLE 10.    Industry impact forces

TABLE 11.    Prostacyclin and prostacyclin analogs market size, by region, 2016 – 2020 (USD Million)

TABLE 12.    Prostacyclin and prostacyclin analogs market size, by region, 2021 – 2027 (USD Million)

TABLE 13.    Soluble guanylate cyclase (SGC) stimulators market size, by region, 2016 – 2020 (USD Million)

TABLE 14.    Soluble guanylate cyclase (SGC) stimulators market size, by region, 2021 – 2027 (USD Million)

TABLE 15.    Endothelin receptor antagonist (ERA) market size, by region, 2016 – 2020 (USD Million)

TABLE 16.    Endothelin receptor antagonist (ERA) market size, by region, 2021 – 2027 (USD Million)

TABLE 17.    Phosphodiesterase 5 (PDE-5) market size, by region, 2016 – 2020 (USD Million)

TABLE 18.    Phosphodiesterase 5 (PDE-5) market size, by region, 2021 – 2027 (USD Million)

TABLE 19.    Vasodilators market size, by region, 2016 – 2020 (USD Million)

TABLE 20.    Vasodilators market size, by region, 2021 – 2027 (USD Million)

TABLE 21.    Others market size, by region, 2016 – 2020 (USD Million)

TABLE 22.    Others market size, by region, 2021 – 2027 (USD Million)

TABLE 23.    Oral market size, by region, 2016 – 2020 (USD Million)

TABLE 24.    Oral market size, by region, 2021 – 2027 (USD Million)

TABLE 25.    Intravenous market size, by region, 2016 – 2020 (USD Million)

TABLE 26.    Intravenous market size, by region, 2021 – 2027 (USD Million)

TABLE 27.    Inhalation market size, by region, 2016 – 2020 (USD Million)

TABLE 28.    Inhalation market size, by region, 2021 – 2027 (USD Million)

TABLE 29.    North America pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)

TABLE 30.    North America pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 31.    North America pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 32.    North America pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 33.    North America pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 34.    North America pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 35.    U.S. pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 36.    U.S. pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 37.    U.S. pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 38.    U.S. pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 39.    Canada pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 40.    Canada pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 41.    Canada pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 42.    Canada pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 43.    Europe pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)

TABLE 44.    Europe pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 45.    Europe pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 46.    Europe pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 47.    Europe pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 48.    Europe pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 49.    Germany pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 50.    Germany pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 51.    Germany pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 52.    Germany pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 53.    UK pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 54.    UK pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 55.    UK pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 56.    UK pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 57.    France pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 58.    France pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 59.    France pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 60.    France pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 61.    Spain pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 62.    Spain pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 63.    Spain pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 64.    Spain pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 65.    Italy pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 66.    Italy pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 67.    Italy pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 68.    Italy pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 69.    Asia Pacific pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)

TABLE 70.    Asia Pacific pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 71.    Asia Pacific pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 72.    Asia Pacific pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 73.    Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 74.    Asia Pacific pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 75.    Japan pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 76.    Japan pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 77.    Japan pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 78.    Japan pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 79.    China pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 80.    China pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 81.    China pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 82.    China pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 83.    India pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 84.    India pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 85.    India pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 86.    India pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 87.    Australia pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 88.    Australia pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)

TABLE 89.    Australia pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 90.    Australia pulmonary arterial hypertension market size, by route of administration, 2021 - 2027 (USD Million)

TABLE 91.    South Korea pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 92.    South Korea pulmonary arterial hypertension market size, by drug class, 2021 - 2027 (USD Million)

TABLE 93.    South Korea pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 94.    South Korea pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 95.    Latin America pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)

TABLE 96.    Latin America pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 97.    Latin America pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 98.    Latin America pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 99.    Latin America pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 100.    Latin America pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 101.    Brazil pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 102.    Brazil pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 103.    Brazil pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 104.    Brazil pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 105.    Mexico pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 106.    Mexico pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 107.    Mexico pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 108.    Mexico pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 109.    Argentina pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 110.    Argentina pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 111.    Argentina pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 112.    Argentina pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 113.    MEA pulmonary arterial hypertension market size, by country, 2016 - 2020 (USD Million)

TABLE 114.    MEA pulmonary arterial hypertension market size, by country, 2021 – 2027 (USD Million)

TABLE 115.    MEA pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 116.    MEA pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 117.    MEA pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 118.    MEA pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 119.    South Africa pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 120.    South Africa pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 121.    South Africa pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 122.    South Africa pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 123.    Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 124.    Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 125.    Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 126.    Saudi Arabia pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)

TABLE 127.    UAE pulmonary arterial hypertension market size, by drug class, 2016 - 2020 (USD Million)

TABLE 128.    UAE pulmonary arterial hypertension market size, by drug class, 2021 – 2027 (USD Million)

TABLE 129.    UAE pulmonary arterial hypertension market size, by route of administration, 2016 - 2020 (USD Million)

TABLE 130.    UAE pulmonary arterial hypertension market size, by route of administration, 2021 – 2027 (USD Million)
 

Charts & Figures

FIG. 1    Market estimation and forecast methodology

FIG. 2    Top-down approach

FIG. 3    Industry segmentation

FIG. 4    Global pulmonary arterial hypertension market size, 2016 – 2027 (USD Million)

FIG. 5    Growth potential analysis, by drug class

FIG. 6    Growth potential analysis, by route of administration

FIG. 7    Porter’s analysis

FIG. 8    Competitive matrix analysis

FIG. 9    PESTEL analysis

FIG. 10    Key segment trends, by drug class

FIG. 11    Key segment trends, by route of administration

FIG. 12    Key regional trends

FIG. 13    Competitive dashboard, 2020
 

Authors: Sumant Ugalmugale, Rupali Swain

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Published Date: Aug 2021
  • Companies covered: 7
  • Tables & Figures: 143
  • Countries covered: 18
  • Pages: 120

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount